Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Azacitidine by Bristol-Myers Squibb for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
Azacitidine is under clinical development by Bristol-Myers Squibb and currently in Phase II for Pancreatic Ductal Adenocarcinoma. According to GlobalData,...
Azacitidine by Bristol-Myers Squibb for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia): Likelihood of Approval
Azacitidine is under clinical development by Bristol-Myers Squibb and currently in Phase II for Acute Myelocytic Leukemia (AML, Acute Myeloblastic...
Azacitidine by Bristol-Myers Squibb for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma): Likelihood of Approval
Azacitidine is under clinical development by Bristol-Myers Squibb and currently in Phase II for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma). According...
Azacitidine by Bristol-Myers Squibb for Diffuse Large B-Cell Lymphoma: Likelihood of Approval
Azacitidine is under clinical development by Bristol-Myers Squibb and currently in Phase II for Diffuse Large B-Cell Lymphoma. According to...